WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, announced the official opening of its advanced therapies testing facility at 400 Rouse Boulevard in Philadelphia’s Navy Yard. The new facility, which includes 140,000 square feet laboratories, will further enhance the company’s Contract Testing, Development and Manufacturing Organization (CTDMO) business model by tripling the company’s previous
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), is celebrating the official opening of the Iovance Cell Therapy Center (iCTC). The iCTC, located at the Philadelphia Navy Yard, is the first centralized, scalable, state-of-the-art manufacturing facility dedicated to producing TIL cell therapies for patients with
Multidisciplinary Team Includes 13 Subject Matter Expert Consultants; More Than 50% are Certified Minority- and Women-owned Business Enterprises PIDC, Philadelphia’s public-private economic development corporation and master developer of the Philadelphia Navy Yard, in partnership with Ensemble Real Estate Investments and Mosaic Development Partners (“Ensemble/Mosaic”), today announced the selection of James Corner Field Operations (“Field Operations”) to
As a historic, thriving waterfront district in Philadelphia, the Navy Yard is bustling with 15k people, 175 companies, and hundreds of career opportunities for all! Take a look at these 20 Navy Yard businesses that you could work for in 2020!
The 95,000 square foot build-to-suit office and laboratory building for WuXi AppTec’s Advanced Therapies Business Unit (WuXi ATU), located at 400 Rouse Boulevard, is moving forward as expected.
Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it has entered into a lease agreement to build an approximately 136,000 square foot commercial-scale production facility at the Philadelphia Navy Yard for commercial and clinical production of autologous TIL products, including its candidate lifileucel.
What a beautiful fall day for the groundbreaking of WuXi AppTec’s 4th Navy Yard facility! WuXi’s Chief Scientific Officer, Dr. Joe Hughes, was joined by Lauren Swartz, Senior Director of International Business at the City of Philadelphia’s Commerce Department; John Grady, President of PIDC; John Gattuso and Brian Cohen of Liberty Property Trust; and other